Table 1 Characteristics of MPN patients... | American Society of Hematology

Table 1

Characteristics of MPN patients with mutations in TET2

UPN	Sex	Diagnosis	Age at diagnosis, y	Disease duration, mo	TET2 mutation	JAK2-V617F, percentage T	JAK2-exon 12, percentage mutation	Complications	Treatment
p021	Male	PV	55	107	p.Thr1372Ile	3	21	None	Aspirin, phlebotomies
p101	Male	ET	61	38	p.Ser1285del	19	NA	Bleeding	Aspirin, hydroxyurea
p136	Male	PV	75	38	p.Gln891X	40	NA	Died, cause of death unknown	NA
p191	Male	PMF	66	59	p.Leu1210Pro	100	NA	Intracranial bleeding, pulmonary Embolism	Oral anticoagulants
p209	Male	PV	64	30	p.Arg544X	88	NA	Post-PV myelofibrosis	Aspirin, hydroxyurea
p225	Female	PV	75	1	splice donor c.3980 + 2G→T	82	NA	Cerebrovascular insult, arterial occlusion	Aspirin, hydroxyurea
p226	Female	PV	49	28	p.Asp1858fs	82	NA	None	Aspirin, hydroxyurea
p234	Male	PV	71	1	p.Gly1275Glu	20	NA	Transient ischemic attack	Clopidogrel, hydroxyurea

UPN	Sex	Diagnosis	Age at diagnosis, y	Disease duration, mo	TET2 mutation	JAK2-V617F, percentage T	JAK2-exon 12, percentage mutation	Complications	Treatment
p021	Male	PV	55	107	p.Thr1372Ile	3	21	None	Aspirin, phlebotomies
p101	Male	ET	61	38	p.Ser1285del	19	NA	Bleeding	Aspirin, hydroxyurea
p136	Male	PV	75	38	p.Gln891X	40	NA	Died, cause of death unknown	NA
p191	Male	PMF	66	59	p.Leu1210Pro	100	NA	Intracranial bleeding, pulmonary Embolism	Oral anticoagulants
p209	Male	PV	64	30	p.Arg544X	88	NA	Post-PV myelofibrosis	Aspirin, hydroxyurea
p225	Female	PV	75	1	splice donor c.3980 + 2G→T	82	NA	Cerebrovascular insult, arterial occlusion	Aspirin, hydroxyurea
p226	Female	PV	49	28	p.Asp1858fs	82	NA	None	Aspirin, hydroxyurea
p234	Male	PV	71	1	p.Gly1275Glu	20	NA	Transient ischemic attack	Clopidogrel, hydroxyurea

UPN indicates unique patient number; PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis; and NA, not applicable.